For the past 12 months, several parties have been connecting with the Group regarding potential acquisition opportunities, including the consortium of Icon China’s senior management.
“The transition of ownership to this consortium is an outstanding result for both our local teams and the patients they care for,” said Mark Middleton OAM, Icon Group CEO.
“Many members of this group have been with Icon China since its early days, playing a pivotal role in improving outcomes for communities that previously had limited or no access to world-class cancer treatment. Knowing these leaders – who understand the needs of the region and carry deep commitment to Icon’s values – will continue to advance our cancer care legacy is both reassuring and humbling.